NBIX, Taisho start Phase IIb diabetes trial

Neurocrine (NBIX) and Taisho (Tokyo, Japan) started a double-blind, placebo-controlled international Phase IIb trial of NBI-6024 therapeutic vaccine to treat new onset Type I diabetes in 400 adult and...